The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

The majority of ILD or pneumonitis events were low grade (grade 1 [n=17 ... “Bringing ENHERTU earlier in the treatment of HER2 positive metastatic breast cancer may represent an important ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

In the ENHERTU arm, the majority of ILD or pneumonitis events were low grade (grade 1 [n=7 ... which represent the first time a HER2 directed medicine has demonstrated a survival benefit in ...

Enhertu (5.4mg/kg) is approved in more than 80 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ ISH-) breast cancer who have received ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

Trastuzumab deruxtecan improves survival in HER2-low and HER2-ultralow breast cancer ... practice changing data have shown that trastuzumab deruxtecan (Enhertu) can improve survival among patients ...

In the DESTINY-Breast06 trial, the ADC trastuzumab deruxtecan (Enhertu) significantly improved progression-free survival in previously treated metastatic hormone receptor-positive/HER2-low or ...

However, the post-Enhertu treatment area is also growing ... s PD-1 inhibitor Tevimbra and chemotherapy in first-line HER2-low gastric or gastroesophageal junction adenocarcinoma.